Atorvastatin calcium: An addition to HMG-CoA reductase inhibitors

Pharmacotherapy

Volumn 17, Issue 6, 1997, Pages 1157-1177

  Chong, Pang H ^a,b   Seeger, John D ^b  

^a Jr Hospital of Cook County   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CLINICAL TRIAL; DIARRHEA; DRUG ACTIVITY; DRUG APPROVAL; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; FLATULENCE; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; NONHUMAN; PAIN; REVIEW;

ANIMALS; ANTICHOLESTEREMIC AGENTS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; PYRROLES;

EID: 0030695362     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). JAMA 1993;269:3015-23.
2. The Expert Panel. Report of the National Cholesterol Education Program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Arch Intern Med 1988;148:36-69.
3. European Atherosclerosis Society. Prevention of coronary heart disease: scientific background and new clinical guidelines. Nutr Metab Cardiovasc Dis 1992;2:113-56.
4. Ginsberg HN, Le N-A, Short MP, et al. Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin: implication for regulation of apolipoprotein B synthesis. J Clin Invest 1987;80:1692-7.
5. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994;344:1383-9.
6. Shepard J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
7. Rackley CE. Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease. Clin Cardiol 1996;19:683-9.
8. Illingworth DR. New horizons in combination drug therapy for hypercholesterolemia. Cardiology 1989;76(suppl 1):83-100.
9. Hunninghake DB. HMG-CoA reductase inhibitors. Curr Opin Lipidol 1992;3:22-8.
10. Illingworth DR, Tobert JA. A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin Ther 1994;16:366-85.
11. Parke-Davis Pharmaceuticals. Atorvastatin (Lipitor) oral package insert. Ann Arbor, MI; 1996.
12. Kearney AS, Crawford LF, Mehta SC, Radebaugh GW. The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxyacid forms of the HMG-CoA reductase inhibitor, CI-981. Pharm Res 1993;10:1461-5.
13. Gmerek AM, Yang H, Bays H, et al. Atorvastatin causes dose-dependent reduction in LDL cholesterol and triglycerides. In: Abstracts of the 66th congress of the European Atherosclerosis Society, Florence, July 13-17, 1996. Houston: Giovanni Lorenzini Medical Foundation, 1996:212.
14. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vase Biol 1995;15:678-82.
15. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232:34-7.
16. Schaefer EJ, Levy RI. Pathogenesis and management of lipoprotein disorders. N Engl J Med 1985;312:1300-10.
17. Grundy SM. Cholesterol and coronary artery disease. A new era. JAMA 1986;256:2849-58.
18. Ross R. The pathogenesis of atherosclerosis-an update. N Engl J Med 1986;314:488-500.
19. Goldstein JL, Brown MS. Familial hypercholesterolemia: a genetic receptor disease. Hosp Pract 1985;2:35-46.
20. Goldstein JL, Kita T, Brown MS. Defective lipoprotein receptors and atherosclerosis. Lessons from the animal counterpart of familial hypercholesterolemia. N Engl J Med 1983;309:288-96.
21. Hoeg JM, Brewer HB Jr. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of hypercholesterolemia. JAMA 1987;258:3532-6.
22. Tobert JA. New developments in lipid-lowering therapy; the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase. Circulation 1987;76:534-8.
23. Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 1988;319:24-33.
24. Jungnickel PW, Cantral KA, Maloney PA. Drug review: pravastatin: a new drug for the treatment of hypercholesterolemia. Clin Pharm 1992;11:677-89.
25. Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996;275:128-33.
26. Ma PTS, Gil G, Sudof TC, et al. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptors in liver of hamsters and rabbits. Proc Natl Acad Sci USA 1986;83:8370-4.
27. Grundy SM. HMG-CoA reductase inhibitors: clinical applications and therapeutics potential. In: Rifkind BM, ed. Drug treatment of hyperlipidemia. New York: Marcel Dekker, 1991:139-67.
28. Heinonen T, Stein E, Weiss S, et al. The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a randomized, double-masked study. Clin Ther 1996;18(5): 853-63.
29. Goh EH, Heimer M. Effects of free fatty acids on activity of hepatic microsomal 3-hydroxy-3-methylglutaryl-coenzyme A reductase and on secretion of triglycerides and cholesterol by liver. J Biol Chem 1977;252:2822-6.
30. Kasim SE, LeBoeuf RC, Khilnani S, Tallapaka L, Dayananda D, Jen KL. Mechanisms of triglyceride-lowering effect of HMG-CoA reductase inhibitor in a hyperglyceridemic model, the Zuker obese rat. J Lipid Res 1992;33:1-7.
31. Marais AD, Firth JC, Bateman M, Jones J, Mountney J, Martens C. Atorvastatin is a powerful and safe agent for lowering plasma cholesterol concentration in heterozygous familial hypercholesterolemia [abstr 226]. Atherosclerosis 1994;109(special issue):316.
32. Krause BR, Bousley R, Kieft K, Stanfield R, Newton RS. CI-981 is superior to lovastatin for lowering plasma triglycerides in experimental animals [abstr 3289]. FASEB J 1993;7:A567.
33. Auerbach BJ, Krause BR, Bisagaier CL, Newton RS. Comparative effects of HMG-CoA reductase inhibitors on apo B production in the casein-fed rabbit: atorvastatin versus lovastatin. Atherosclerosis 1995;115:173-80.
34. Plosker GL, McTavish D. Simvastatin: a reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolemia. Drugs 1996;50:334-63.
35. Bocan T, Mazur MJ, Muller SB, et al. Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation. Atherosclerosis 1994;111:127-42.
36. Corsini A, Mazzotti M, Raiteri M, et al. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. Atherosclerosis 1993;101:117-25.
37. Soma MR, Donetti E, Parolini C, et al. HMG-CoA reductase inhibitors: in vivo effect on carotid intimai thickening in normal cholesterolemic rabbits. Arterioscler Thromb 1993;13:571-8.
38. Alessandri C, Basili S, Maurelli M, et al. Effects of hydroxymethylglutaryl-coenzyme A reductase inhibitors on some blood coagulation parameters. Curr Ther Res 1993;53:188-95.
39. Radulovic LL, Cilla DD Jr, Posvar EL, Sedman AJ, Whitfleld LR. Effect of food on the bioavailability of atorvastatin, an HMG-CoA reductase inhibitor. J Clin Pharmacol 1995;35:990-4.
40. Posvar EL, Radulovic LL, Cilla DD Jr, Whitfield LR, Sedman AJ. Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects. J Clin Pharmacol 1996;36:728-31.
41. Gibson DM, Bron NJ, Richens A, Hounslow NJ, Sedman AJ, Whitfield LR. Effect of age and gender on pharmacokinetics of atorvastatin in humans. J Clin Pharmacol 1996;36:242-6.
42. Cilla DD Jr, Radulovic LL, Whitfield LR, Posvar EL, Sedman AJ. Safety, tolerance, and pharmacokinetic (PK) profiles following single-dose of CI-981, a potent HMG-CoA reductase inhibitor [abstr]. Pharm Res 1993;10(suppl):S-332.
43. Cilla DD Jr, Gibson DM, Whitfield LR, Sedman AJ. Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening. J Clin Pharmacol 1996;36:604-9.
44. Bocan TM, Ferguson E, McNally W, et al. Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: comparison with selected HMG-CoA reductase inhibitors. Biochim Biophys Acta 1992;1123: 133-44.
45. Gibson DM, Cilla DD Jr, Posvar EL, et al. Pharmacokinetic characteristics of CI-981 as a function of morning-versus-evening dosing in healthy volunteers [abstr]. Pharm Res 1993;10(suppl):S-340.
46. Blum C. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. A symposium: HMG-CoA reductase inhibitors. Am J Cardiol 1994;73(14):3D-10.
47. Yang, BB, Hounslow NJ, Sedman AJ, Forgue ST. Effects of atorvastatin, an HMG-CoA reductase inhibitor, on hepatic oxidative metabolism of antipyrine. J Clin Pharmacol 1996;36:356-60.
48. Whitfield LR, Cilla DD Jr, Posvar EL, Sedman AJ, Ginson DM. Single- and multiple-dose pharmacokinetics of CI-981, a potent HMG-CoA reductase inhibitor [abstr PPDM 8167]. Pharm Res 1993;10(suppl):S-340.
49. Woodhouse KW, Wynne HA. Age-related changes in liver and hepatic blood flow: the influence on drug metabolism in the elderly. Clin Pharmacokinet 1983;15:287-94.
50. Cheng H, Rogers JD, Sweany AE, et al. Influence of age and gender on the plasma profiles of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin. Pharm Res 1992;9:1629-33.
51. Pan HY, Waclawski AP, Funke PT, Whigan D. Pharmacokinetics of pravastatin in elderly versus young men and women. Ann Pharmacother 1993;27:1029-33.
52. Parker TSD, McNamara DJ, Brown C, et al. Mevalonic acid in human plasma: relationship of concentration and circadian rhythm to cholesterol synthesis rates in man. Proc Natl Acad Sci USA 1982;79:3037-41.
53. McKenny JM. Lovastatin: a new cholesterol-lowering agent. Clin Pharm 1988;7:21-36.
54. Illingworth DR. Comparative efficacy of once versus twice daily mevinolin in the therapy of familial hypercholesterolemia. Clin Pharmacol Ther 1986;40:338-43.
55. Hunninghake DB, Melles MJ, Goldberg AC, et al. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. II. Once daily versus twice daily dosing. Atherosclerosis 1990;85:219-27.
56. Saito Y, Yoshida S, Nakaya N, Hata Y, Goto Y. Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects: a double-blind comparative study. Arterioscler Thromb 1991;11:816-26.
57. Levy RI, Troendle AJ, Fattu JM. A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin. Circulation 1993;87(suppl III):III-45-53.
58. Pan HY, DeVault AR, Brescia D, Willard WA. Comparative efficacy of once-daily versus twice daily pravastatin in primary hypercholesterolemia. Clin Ther 1991;13:368-72.
59. Insull W, Black D, Dujovne C, et al. Efficacy and safety of once-daily versus twice dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia. Arch Intern Med 1994;154:2449-55.
60. Triscari J, Pan H, DeVault A, Rossi L, Smith S, Wang-Iverson D. Comparative bioavailability of pravastatin following morning and evening dosing [abstr FIIII-19]. Clin Pharmacol Ther 1991;49:178.
61. Heinonen T, Schrott H, McKenney J, et al. Atorvastatin, a new HMG-CoA reductase inhibitor as monotherapy and combined with colestipol. J Cardiovasc Pharmacol Ther 1996;1:117-22.
62. Parke-Davis. Data on file. Ann Arbor, MI; 1997.
63. Minsker DH, MacDonald JS, Robertson RT, Bokelman DL. Mevalonate supplements in pregnant rats suppresses the teratogenicity of mevinolinic acid, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Teratology 1983;28:449-56.
64. U.S. Food and Drug Administration. Summary basis for approval of NDA 20-261 (fluvastatin). Pharmacology review of amendment conducted August 1988. Washington, DC: Author, 1993.
65. Tanase T, Hirose K. Reproduction study of pravastatin sodium administered during the period of fetal organogenesis in rats. Jpn Pharmacol Ther 1987;15:4983-94.
66. Tanase T, Asai M, Hirose K. Reproduction study of pravastatin sodium administered during the period of fetal organogenesis in rabbits. Jpn Pharmacol Ther 1987;15:5005-11.
67. Wise LD, Majka JA, Robertson RJ, et al. Simvastatin (MK-0733): oral teratogenicity in rats. Pre- and postnatal observation. Oyo Yakuri/Pharmacometrics 1990;39:143-50.
68. Dostal LA, Schardein JL, Anderson JA. Developmental toxicity of the HMG-CoA reductase inhibitor, atorvastatin, in rats and rabbits. Teratology 1994;50:387-94.
69. Bakker-Arkema R, Fayyad R, Davidson M, et al. One-year study comparing the safety and efficacy of atorvastatin to that of lovastatin. In: Abstracts of the 66th congress of the European Atherosclerosis Society, Florence, July 13-17, 1996. Houston: Giovanni Lorenzini Medical Foundation, 1996:205.
70. Egros F, Langan J, Bertolini S, et al. A one-year study comparing atorvastatin and pravastatin in patients with hypercholesterolemia. In: Abstracts of the 66th congress of the European Atherosclerosis Society, Florence, July 13-17, 1996. Houston: Giovanni Lorenzini Medical Foundation, 1996:222.
71. Bracs P, Dart A, Craig H, et al. A one-year study comparing atorvastatin and simvastatin in patients with hypercholesterolemia. In: Abstracts of the 66th congress of the European Atherosclerosis Society, Florence, July 13-17, 1996. Houston: Giovanni Lorenzini Medical Foundation, 1996:205.
72. Anonymous. FDC reports: the pink sheet, April 17. 1995;57:12.
73. McCormick L, Wagner B, Pressler M, et al. Is medical therapy a reasonable alternative to a catheter based revascularization (CR)? In: Abstracts of the 66th congress of the European Atherosclerosis Society, Florence, July 13-17, 1996. Houston: Giovanni Lorenzini Medical Foundation, 1996:205.
74. Japan Cholesterol Lowering Atorvastatin Study (J-CLAS) Group. Efficacy of atorvastatin in primary hypercholesterolemia. Am J Cardiol 1997;79:1248-52.
75. Naoumova RP, Marais AD, Mountney J, et al. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolemia. Atherosclerosis 1996;119:203-13.
76. Wagner B, Huwel D, Rehorst D, Smilde JG, Wunderlich J, Black D. One-year treat-to-larget study of atorvastatin vs. pravastatin in risk-stratified hypercholesterolemic patients. In: Abstracts of the 66th congress of the European Atherosclerosis Society, Florence, July 13-17, 1996. Houston: Giovanni Lorenzini Medical Foundation, 1996:205.
77. Best JD, Nicholson GC, O'Neal DN, Kotowicz M, Sanders K. Atorvastatin and simvastatin reduce elevated LDL-cholesterol in type 2 diabetes [abstr 211]. Atherosclerosis 1994;109:312.
78. Nawrocki J, Schwartz S, Fayyad R, Simunovic L. Atorvastatin, a new HMG-CoA reductase inhibitor is safe and effective in NIDDM patients with hyperlipidemia. In: Abstracts of the 66th congress of the European Atherosclerosis Society, Florence, July 13-17, 1996. Houston: Giovanni Lorenzini Medical Foundation, 1996:222.
79. Seiler KU, Wolffenbuttel BHR, Mahla G, et al. Comparison of atorvastatin, a new HMG-CoA reductase inhibitor, with pravastatin and simvastatin [abstr 217]. Atherosclerosis 1994;109:314.
80. The Lipid Research Clinics Coronary Primary Prevention Trial Results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64.
81. Naoumova RP, Marais D, Firth JC, Neuwirth KY, Taylor GW, Thompson GR. Atorvastatin augments therapy of homozygous familial hypercholesterolemia by inhibiting upregulation of cholesterol synthesis after apheresis and bile acid sequestrant. Circulation 1997;94(8 suppl):I-583.
82. Austin MA. Plasma triglycerides as a risk factor for coronary heart disease: the epidemiologic evidence and beyond. Am J Epidemiol 1989;129:245-59.
83. Austin MA. Plasma triglyceides and coronary heart disease. Arterioscler Thromb Vase Biol 1991;11:2-14.
84. Patsch JR. Triglyceride-rich lipoproteins and atherosclerosis. Atherosclerosis 1994;110(suppl):523-6.
85. Kirk JK, Dupuis RE. Approaches to the treatment of hyperlipidemia in the solid organ transplant recipient. Ann Pharmacother 1995;29:79-91.
86. Barbir M, Hunt B, Galloway D, et al. A randomized pilot trial of low-dose combination lipid-lowering therapy following coronary artery bypass grafting. Clin Cardiol 1994;17:59-64.
87. Bristol-Myers Squibb, Co. Pravastatin (Pravachol) oral package insert. Princeton, NJ; 1993.
88. Merck & Co. Lovastatin (Mevacor) oral package insert. West Point, PA; 1992.
89. Merck & Co. Simvastatin (Zocor) oral package insert. West Point, PA; 1993.
90. Sandoz Pharmaceutical Co. Fluvastatin (Lescol) oral package insert. East Hanover, NJ; 1994.
91. Ciaravino V, Kropko ML, Rothwell CE, Hovey CA, Theiss JC. The genotoxicity profile of atorvastatin, a new drug in the treatment of hypercholesterolemia. Mutation Res 1995;343:95-107.
92. Cardinale V, ed. Drug topics. Red book and updates. Montvale, NJ: Medical Economics, 1997.
93. Kong SX, Gandhi SK, Crawford SY, Seeger JD. Pharmacoeconomic evaluation of HMG-CoA reductase inhibitors in the treatment of hypercholesterolemia. Am J Managed Care 1996;2:1055-73.
94. Wade WE, Spruill WJ, Taylor AT, Longe RL, Hawkins DW. The expanding role of pharmacy and therapeutics committees: the 1990s and beyond. Pharmacoeconomics 1996;10:123-8.
95. Black DM. Atorvastatin: a step ahead for HMG-CoA reductase inhibitors. In: Woodford FP, Davignon J, Sniderman A, et al, eds. Atherosclerosis X. New York: Elsevier Science B.V., 1995:307-10.
96. Sacks FM, Pfeffer MA, Maye LA, et al. The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335(14):1001-9.